Teladoc Health, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024. The company's total revenue decreased by 3% year-over-year to $640.5 million in Q4 2024, and by 1% to $2,569.6 million for the full year 2024.
The net loss widened significantly to $48.4 million, or $0.28 per share, in Q4 2024, compared to a loss of $28.9 million, or $0.17 per share, in Q4 2023. For the full year 2024, the net loss totaled $1,001.2 million, or $5.87 per share, which included a non-cash goodwill impairment charge of $790.0 million related to the BetterHelp segment.
Adjusted EBITDA for Q4 2024 decreased by 35% to $74.8 million, with the BetterHelp segment's adjusted EBITDA declining by 63% to $21.7 million. Teladoc Health provided guidance for Q1 2025, expecting revenue between $608 million and $629 million, and full-year 2025 revenue between $2,468 million and $2,576 million, with an adjusted EBITDA outlook of $278 million to $319 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.